This combination treatment enhanced adoptive cell therapy by diminishing the immunosuppressive characteristics of the TME.189 IL-2 can be encoded by NDV190–192 and HSV,193 and it has shown antitumor efficacy against the TME and in the spleen of a late-stage tumor model, as determined by the percentages of activated CD4+Foxp3− and CD8+IFN-γ+ T cells. The gene discussed is IFNG; the disease is neoplasm.